Securing our Radioactive Materials Act

Standing with Moms ActThis bill requires the Department of Health and Human Services (HHS) to disseminate information about pregnancy-related resources, including information about abortion risks and alternatives.Specifically, HHS must create a public website called life.gov that lists such resources that are available through federal, state, and local governments and private entities.Additionally, HHS must create on its existing website a portal that provides a user, based on the user's responses to a series of questions, tailored information about pregnancy resources available in the user's zip code and risks related to abortion. HHS must develop a plan to conduct follow-up outreach to users of the portal (if the user consents to the outreach). States must recommend resources that meet criteria set by HHS for inclusion in the portal. HHS may award grants to states to establish or support a system that aggregates resources to include in the portal.Further, the Health Resources and Services Administration must share information about the new website and portal through the National Maternal Mental Health Hotline.HHS must also ensure that the new website and hotline are available to families who speak languages other than English.The new website, portal, and hotline may not include resources provided by entities that (1) perform, induce, refer for, or counsel in favor of abortions; or (2) financially support such entities.The bill also requires HHS to report on traffic to the new website and portal, gaps in services available to pregnant and postpartum individuals, and related matters.

Spectrum Pipeline Act of 2025

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 or the MIRACLE Medical Technology Act of 2025This bill requires the Department of Health and Human Services (HHS) to implement a program for the United States and Israel to collaborate on developing and delivering health care products and services. The program must include coordinated activities in specified areas, including research and development, use of innovative technology, intellectual property protection, regulatory harmonization, disease prevention, and biological product manufacturing. The bill authorizes HHS to establish a joint United States-Israel Health Care Collaboration Center in the United States to leverage existing expertise for advancing the program’s purposes.

Voluntary Sustainable Apparel Labeling Act

Reducing Drug Prices for Seniors Act

Communications Security ActThis bill provides statutory authority for a council established by the Federal Communications Commission (FCC) to provide advice regarding the security, reliability, and interoperability of communications networks. (This advice is currently provided by the FCC’s Communications Security, Reliability, and Interoperability Council.)The bill specifies that the FCC may designate an existing advisory committee to fulfill this role, provided the committee’s membership is modified, as necessary, to comply with membership requirements set forth in the bill. Specifically, the bill requires the council to include, to the extent practicable, representatives of companies in the communications industry; public interest organizations or academic institutions; and federal, state, tribal, and local governments (with at least one member representing each level of government). Members are to be selected by the FCC's chair and generally may not include representatives of entities owned or controlled by, or subject to the influence of, a foreign adversary, or otherwise deemed to pose a threat to U.S. national security. Under current law, federal advisory committees must generally terminate after two years unless they are renewed or a statute specifies a different termination date. However, the bill exempts the council from this requirement.

Recognizing the seriousness of polycystic ovary syndrome (PCOS) and expressing support for the designation of the month of September as "PCOS Awareness Month".

Dental Loan Repayment Assistance Act of 2025

DIGITAL Applications Act Deploying Infrastructure with Greater Internet Transactions And Legacy Applications Act

Understanding Cybersecurity of Mobile Networks ActThis bill requires the National Telecommunications and Information Administration to examine and report on the cybersecurity of mobile service networks and the vulnerability of these networks and mobile devices to cyberattacks and surveillance conducted by adversaries.The report must include, among other items, (1) an assessment of the degree to which mobile service providers have addressed certain cybersecurity vulnerabilities; (2) a discussion of the degree to which these providers have implemented cybersecurity best practices and risk assessment frameworks; and (3) an estimate of the prevalence and efficacy of encryption and authentication algorithms and techniques.

Climate and Health Protection Act

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

To amend the Horse Protection Act to provide increased protection for horses participating in shows, exhibitions, sales, and auctions, and for other purposes.